New Brazil data shows disappointing 50.4% efficacy for China's CoronaVac vaccine
On Jan 12, researches said that a coronavirus vaccine developed by China’s Sinovac Biotech was just 50.4% effective, barely enough for regulatory approval and well below the rate announced a week before, at preventing symptomatic infections in a Brazilian trial.
Researchers at Butantan delayed announcement of their results three times, blaming a confidentiality clause in a contract with Sinovac.
Butantan officials said the design of the Brazilian study, focusing on frontline health workers during a severe outbreak in Brazil and including elderly volunteers, made it impossible to compare the results directly with other trials or vaccines.
Source: Reuters #Jan13
https://www.reuters.com/article/us-health-coronavirus-brazil-coronavirus/brazil-researchers-report-more-modest-50-4-efficacy-for-chinas-coronavac-idUSKBN29H2CE
#Brazil #Sinvac #Covid19Vaccine #VaccinTrial
On Jan 12, researches said that a coronavirus vaccine developed by China’s Sinovac Biotech was just 50.4% effective, barely enough for regulatory approval and well below the rate announced a week before, at preventing symptomatic infections in a Brazilian trial.
Researchers at Butantan delayed announcement of their results three times, blaming a confidentiality clause in a contract with Sinovac.
Butantan officials said the design of the Brazilian study, focusing on frontline health workers during a severe outbreak in Brazil and including elderly volunteers, made it impossible to compare the results directly with other trials or vaccines.
Source: Reuters #Jan13
https://www.reuters.com/article/us-health-coronavirus-brazil-coronavirus/brazil-researchers-report-more-modest-50-4-efficacy-for-chinas-coronavac-idUSKBN29H2CE
#Brazil #Sinvac #Covid19Vaccine #VaccinTrial